Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 6;12:4299–4322. doi: 10.2147/IJN.S136766

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Shen et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

In vitro cell viability of HeLa cells (A) and EMT-6 cells (B) treated with free DOX, LDM-PLGA/PPF, and LM-PLGA/PPF with different DOX concentrations for 48 h with or without preincubation with free folic acid (1.25 mM). (C) Synergistic therapy efficacy of LDM-PLGA/PPF/VEGF shRNA nanocomposites against EMT-6 cells at 25 μg/mL of DOX concentration for 72 h. (D) Fluorescence microscopy images of calcein-AM and propidium iodide costaining of HeLa cells after various treatments at a DOX concentration of 20 μg/mL. Green and red colors represent live and dead cells, respectively. *P<0.05.

Abbreviations: DOX, doxorubicin; PLGA, poly(d,l-lactic-co-glycolic acid); PPF, PEI-PEG-FA; PEI-PEG-FA, polyethyleneimine premodified with polyethylene glycol-folic acid; shRNA, small hairpin RNA; VEGF, vascular endothelial growth factor.